Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer

Ashraf Mohamadkhani, Mohammad Reza Akbari, Reza Ghanbari, Elnaz Naderi, Parisa Rezanejad-Asl, Akram Pourshams

ABSTRACT

BACKGROUND

There are hoarding documents for the biological importance of cyclooxygenase-2 (COX-2) in pancreatic carcinogenesis. We aimed to thoroughly investigate the DNA sequence variations of whole COX-2 exons in a large case-control study of pancreatic cancer by direct sequencing.

METHODS

The entire exonic regions of COX-2 including 10 exons were sequenced in the germline DNA of 96 patients with pancreatic cancer. Selected variants within exons six to seven (E6E7) amplicon from the test panel were genotyped in 96 controls.

RESULTS

The COX-2 gene was demonstrated to be genetically conserved. Four missense mutations were found in three cases. However the common variant c.724-10_724-7delATTT (rs201231411) that is located in intron 6, showed significant difference between cases and controls (21 [21.9%] vs 11 [%11.5], \(p=0.05\)).

CONCLUSION

This study determined that COX-2 has a conservative sequence, which is required for its enzymatic activity and supports the important role of this enzyme’s expression in pancreatic cancer rather than any changes in its activity. The effect of intronic variant rs201231411 on COX-2 expression could be analyzed in future studies.

KEYWORDS

Cyclooxygenase-2 (COX-2); Pancreatic cancer; Genome sequencing

INTRODUCTION

Recent developments in cancer research have discovered the effect of inherited genomic mutations in cancer risk and response to treatment.\(^1\) Pancreatic cancer has been characterized by accumulation of a variety of genomic mutations involve in the progression of normal cells to pre-malignant lesions and then to fully invasive tumor cells.\(^2\)

Research activities in the field of molecular biology of pancreatic ductal adenocarcinoma (PDAC) have increased in the past decades. The incidence rate of this cancer is rising in Iran and it is usually di-
agnosed in advanced stages with no identified risk factors. There are some evidences suggesting that the systemic inflammatory responses associated with chronic pancreatitis play a role in etiology of pancreatic cancer. This suggests that genetic alterations which result in increased inflammatory response and thus chronic inflammation could potentially increase the risk of cancer. One of the genes that code a pro-inflammatory protein is Cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide synthase 2 (PTGS2). This protein converts arachidonic acid to prostaglandins and other eicosanoids. Two cyclooxygenase isoforms, COX-1 and COX-2, whose expressions are regulated by cytokines at both the transcriptional and post-transcriptional levels and are targets of non-steroidal anti-inflammatory drugs (NSAIDs). It is suggested that over-expression of COX-2 results in carcinogenesis through inflammation. In fact, the importance of COX-2 in the etiology of gastrointestinal (GI) cancers is well documented. The increased amounts of COX-2 protein are found in more aggressive tumors with poorer prognosis such as pancreatic cancer. Several works have focused on investigating the expression level of COX-2 and risk of PDAC. However, the role of sequence variation and mutations of the COX-2 gene that may contribute to the risk of PDAC are still unknown. The COX-2 gene is 8 kb in length and has 10 protein-coding exons. This gene is located on the human chromosome 1q25.2--q25.3.

In this study, we analyzed the genomic alteration in the entire exons 1 to 10 of COX-2 gene to investigate the relationship between COX-2 mutations and the risk of pancreatic cancer.

MATERIALS AND METHODS

Study Population and Sample Collection

Ninety six patients diagnosed with pancreatic cancer were recruited at the Department of Gastroenterology of Shariati Hospital, Tehran, Iran, during July 2010 and March 2012. The inclusion criteria consisted of confirmed diagnosis of pancreatic cancer confined to the pancreas both histologically and clinically. In order to provide a matched control cohort, 96 healthy controls were included from a random sampling from the Health Examination Cohort. All individuals completed a self-administered questionnaire and blood samples were collected by venipuncture into EDTA glass tubes. The participants received genetic counseling for relatives affected at the Digestive Disease Research Institute and all provided written informed consent.

DNA Extraction

Blood samples were centrifuged at 2,000g for 10 minutes and the buffy coats were separated manually. DNA was extracted using the Gentra Puregene kit according to the manufacturer’s recommendation (Qiagen, Alameda, CA, USA).

COX-2 Amplification and Sequencing

The COX-2 sequence was obtained from NCBI build 37 reference assembly with NCBI Reference Sequence: NG_028206.1 (PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) [Homo sapiens (human)]). Primers for amplifying all 10 COX-2’s exons were designed by Primer 3 software. All PCRs were done in total volume of 25 ul comprising 19.8 ul H2O, 2.5 ul 10x reaction buffer, 0.5 ul dNTP (10 mM), 0.2 ul Taq DNA polymerase (Qiagen Hot Start kit) and 0.5 ul of each forward and reverse primers (20 uM). The PCR started with 10 min at 96°C and followed by 45 cycles of 30 sec at 96°C, 30 sec at Tm of 60-63°C and 30 sec at 72°C and was ended by 10 min at 72°C. The DNA fragments of PCR products were sequenced by the Big Dye Terminator Cycle Sequencing kit on an ABI 3500xl DNA Analyzer (Applies Biosystems Inc.). All sequences were matched to the COX-2 reference sequence using Phred & -Phrap software. In the second step, selected variants which were located within two exons 6 to 7 in the test panel were genotyped in the control group using direct sequencing.

Statistical Analysis

Different characteristics of cases and controls were compared using independent t-test and Chi-square test as appropriated. Logistic regression analysis was used for adjusting the comparison of mutation frequencies of cases and controls for potential confounding factors.
covariates. Two-sided p values were reported, and p<0.05 was considered statistically significant. All analyses were done by STATA software (version 12, StataCorp, College Station, TX, USA A).

RESULTS

Study Population

The overall study population included 96 patients with pancreatic cancer and 96 controls. As shown in table 2, the mean age and sex were different between case and controls; therefore, a logistic regression test was used for adjusting the comparison of variant frequencies between cases and controls for age and sex.

COX-2 Sequencing Analysis

Alteration in sequences of all COX-2 exons and two intronic regions (intron 2 and 6) in the group of cases were analyzed compared with the reference sequence. The list of COX-2 nucleotide changes of germline DNA and their frequencies among patients are shown in table 3.

Sequencing of all exons and the adjacent introns in 96 patients with pancreatic cancer revealed four missense mutations in three patients and a deletion in intron 6 (c.724-10_724-7delATTT) in 19 patients. None of the four missense mutations have been reported previously in public databases. Gln at codon 227 and Arg at codons 226 and 442 are highly conserved in different species and any changing of these amino acids is predicted to be pathogenic by in silico tools like mutation taster. For further investigating the differences between frequencies of these variants among cases and controls and their possible association with risk of developing pancreatic cancer, the three missense variants at codon 226 and 227 and also the intronic variant were genotyped among 96 healthy controls by direct sequencing of the exons 6 and 7 of COX-2 gene. None of the three missense variants was seen among controls, but the intronic variant (c.724-10_724-7delATTT) was seen in 11 controls indicating an association with pancreatic cancer with a borderline significance (19.7% vs 11.5%, OR=2.16, 95% CI: 1.00-4.78, p=0.05). After adjusting the comparison for covariates presented in table 4, the same trend was still observed (OR= 2.15, 95% CI: 0.88-5.27, p=0.09).

DISCUSSION

Previous studies offered a major role for enzymes that are involved in the prostaglandin-synthesis pathway (such as COX-2), in the initiation and progression of series of cancers. The activation of COX-2 most often occurs during inflammation which
is a known etiological factor for pancreatic cancer.\textsuperscript{15} The importance of COX-2 in etiology of pancreatic cancer has been supported by application of COX-2 inhibitors which attenuated the tumorigenecity of pancreatic cells.\textsuperscript{16,17} Increased level of this enzyme in patients with pancreatic cancer also associated with short survival in several studies.\textsuperscript{2,16} The mechanism by which COX-2 promotes the tumorigenecity is explained by activation of anti-apoptosis pathway and stimulating the expression of multiple positive regulators of cell cycle and cell migration.\textsuperscript{14}

In this study we present, for the first time, sequencing and analysis of the whole exons in addition to two intronic regions (intron 2 and 6) of COX-2 in human genome of patients with pancreatic cancer. We scanned COX-2 in the germline DNA of 96 cases of pancreatic cancer. As was estimated, we did not see any loss of function mutations, such as a stop codon or frame-shift insertions or deletions among exonic regions in our cases. Since COX-2 activity should be elevated for increasing cancer risk and this gene could be considered as an oncogene, then the cancer predisposing mutations in coding region of this gene should result in gain of function. It is possible that the three missense mutations at two adjacent codons (226-227) seen in three pancreatic cancer cases result in increased enzymatic activity of the COX2 protein that could be evaluated in future research. Furthermore, an intronic variant rs2101231411 with a borderline significance was more frequent in the germline DNA of cases, compared to controls. This intronic variant has been reported in G1000 samples with a MAF (should be spelled out first) of 0.05 which is consistent with the frequency among our 96 controls. The intronic regions do not translate to amino acid sequences, but they could potentially affect the protein product by changing the splicing site in RNA and therefore the final mRNA product.\textsuperscript{18} The effect of COX2 c.724-10_724-7delATTT variant on the splicing of the COX2 RNA is unknown and there is no information about mRNA isoform with deletion of exons around this mutation. Although the association of nucleotide substitution in the promoter region of COX-2 with the increased

| Table 2: Characteristics of study participants |
|-----------------|-----------------|-----------------|-----------------|
| Variable       | Cases, N=96     | Controls, N=96  | p-value         |
| Age (years)    | 63.96±9.7       | 55.34±15.6      | <0.001          |
| Gender, M/F    | 64/32           | 47/49           | 0.013           |
| Tobacco        | 8 (8.3)         | 16 (17.4)       | 0.063           |
| Alcohol        | 7 (7.4)         | 2 (2.2)         | 0.097           |
| Opium          | 20 (20.8)       | 23 (24.7)       | 0.523           |

| Table 3: The characteristics and frequencies of COX-2 identified variants in 96 patients in comparison with each allele MAF in ESP6500 |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Gene            | Amplicon        | DNA Change      | Protein Change  | Mutation Type   | Frequency (%)   | MAF in ESP6500* | rs#              |
| COX2            | E9              | c.1325G>A       | p.Arg442Lys     | Missense        | 1(1.04)         | 0               | NA               |
| COX2            | E6E7            | c.678A>C        | p.Arg226Ser     | Missense        | 1(1.04)         | 0               | NA               |
| COX2            | E6E7            | c.680A>C        | p.Gln227Pro     | Missense        | 1(1.04)         | 0               | NA               |
| COX2            | E6E7            | c.681G>T        | p.Gln227His     | Missense        | 2(2.08)         | 0               | NA               |
| COX2            | E6E7            | c.724-10_724-7delATTT | Intrinsic Deletion | 19(19.7) | 0.05 | rs201231411 |

*The latest frequencies from the NHLBI Exome Sequencing Project

| Table 4: Logistic regression analysis for intronic variant (c.724-10_724-7delATTT) |
|-----------------|-----------------|-----------------|-----------------|
| | OR (95% CI) | p-value         |
| Unadjusted      | c.724-10_724-7delATTT | 2.16 (1.00-4.78) | 0.050          |
| Adjusted*       | c.724-10_724-7delATTT | 2.15 (0.88-5.27) | 0.092          |

* Model was adjusted for age, sex, smoking, alcohol consumption and opium use
expression level of this enzyme and thus higher risk of AML should be spelled out first as well as colon cancer has been reported previously.\(^\text{19,20}\) There is no data about variant in this region and over expression of COX-2 in pancreatic cancer that might be useful to be assessed in future.

In summary, this study determined that COX-2 has a conservative sequence and germline mutations in COX-2 exons are rare to be associated with pancreatic cancer. However we found a borderline significant difference of intronic deletion c.724-10_724-7 (rs201231411) between patients with pancreatic cancer with the control group. This finding is consistent with the biological function of the introns that control the expression of a particular gene and also support the importance of COX-2 expression and risk of pancreatic cancer that have been investigated previously. Our results also recommend that whole genome sequencing is a valuable tool for understanding variations in the human genome and in common serious diseases in our population.

ACKNOWLEDGMENT

Authors of this article take this chance to thank all patients who participated in this research program.

Funding/ Support: This study was supported by grants from the Digestive Disease Research Institute, Tehran University of Medical Sciences.

Authors’ contributions: All authors contributed both to the research and the discussion and they have read and approved the final manuscript.

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

REFERENCES

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
3. Farrokhzad S, Nedjat S, Kamangar F, Kamali M, Malekzadeh R, Pourshams A. Validity and reliability of a questionnaire designed to assess risk factors of pancreatic cancer in Iran. Arch Iran Med 2014;17:102-5.
4. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008;22:65-73.
5. Naderi E, Mostaﬁ M, Pourshams A, Mohamadkhani A. Network of microRNAs-mRNAs Interactions in Pancreatic Cancer. Biomed Res Int 2014;2014:534821.
6. Zogopoulos G, Rothenmund H, Eppel A, Ash C, Akbari MR, Hedley D, et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 2007;121:635-7.
7. Mohamadkhani A, Naderi E, Sharaﬁkhah M, Fazli HR, Moradzadeh M, Pourshams A. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. J Oncol 2013;2013:738915.
8. Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 2001;11:752-60.
9. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-8.
10. Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, et al. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot Essent Fatty Acids 2002;66:13-8.
11. Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the-science. Cancer lett 2014;345:249-57.
12. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006;59:382-6.
13. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010;7:575-6.
14. Cebola I, Peinado MA. Epigenetic deregulation of the COX pathway in cancer. Prog Lipid Res 2012;51:301-13.
15. Hasan S, Satake M, Dawson DW, Funahashi H, Angst E, Go VL, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008;37:121-7.
16. Li W, Mao Z, Fan X, Cui L, Wang X. Cyclooxygenase 2 promoted the tumorigenicity of pancreatic cancer cells. Tumour Biol 2014;35:2271-8.
17. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2014;23:1254-63.
18. Jeffares DC, Mourier T, Penny D. The biology of intron gain and loss. Trends Genet 2006;22:16-22.
19. Zheng J, Chen S, Jiang L, You Y, Wu D, Zhou Y. Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol 2011;87:486-93.
20. Tsuji M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.